Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GBL

This article was originally published in The Tan Sheet

Executive Summary

Senate passes by voice vote the "Samantha Reid and Hillory J. Farias Date-Rape Drug Prohibition Act of 1999" (S 1561) Nov. 19 and returns it to the House; slightly different companion legislation had passed the House 423-1 on Oct. 12 ("The Tan Sheet" Oct. 18, In Brief). Introduced by Sen. Spencer Abraham (R-Mich.), the bill would classify gamma hydroxybutyric acid (GHB) and gamma butyrolactone (GBL) as controlled substances, would require the HHS secretary to develop a national awareness campaign educating consumers about such products and would establish a special unit at DEA to deal with drugs used for sexual assault. Certain regulatory exemptions are provided for researchers studying GHB for the treatment of narcolepsy. FDA first asked companies manufacturing dietary supplements containing GBL, a GHB precursor, to recall their products in a Jan. 21 "Talk Paper" ("The Tan Sheet" Jan. 25, p. 6)

Related Content

Topics

UsernamePublicRestriction

Register

PS090608

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel